Boston Children's Hospital, Boston, Massachusetts.
Dana-Farber Cancer Institute, Boston, Massachusetts.
Mol Cancer Res. 2019 Jun;17(6):1294-1304. doi: 10.1158/1541-7786.MCR-18-0963. Epub 2019 Feb 18.
Focal amplification of chromosome 1q23.3 in patients with advanced primary or relapsed urothelial carcinomas is associated with poor survival. We interrogated chromosome 1q23.3 and the nearby focal amplicon 1q21.3, as both are associated with increased lymph node disease in patients with urothelial carcinoma. Specifically, we assessed whether the oncogene that resides in 1q21.3 and the genes that reside in the 1q23.3 amplicon were required for the proliferation or survival of urothelial carcinoma. We observed that suppressing MCL1 or the death effector domain-containing protein (DEDD) in the cells that harbor amplifications of 1q21.3 or 1q23.3, respectively, inhibited cell proliferation. We also found that overexpression of MCL1 or DEDD increased anchorage independence growth and increased experimental metastasis in the nonamplified urothelial carcinoma cell line, RT112. The expression of MCL1 confers resistance to a range of apoptosis inducers, while the expression of DEDD led to resistance to TNFα-induced apoptosis. These observations identify and as genes that contribute to aggressive urothelial carcinoma. IMPLICATIONS: These studies identify and as genes that contribute to aggressive urothelial carcinomas.
染色体 1q23.3 局部扩增与晚期原发性或复发性尿路上皮癌患者的不良生存相关。我们检测了染色体 1q23.3 及其附近的焦点扩增子 1q21.3,因为两者都与尿路上皮癌患者淋巴结疾病的增加有关。具体来说,我们评估了位于 1q21.3 中的癌基因和位于 1q23.3 扩增子中的基因是否需要促进尿路上皮癌的增殖或存活。我们观察到,分别抑制携带 1q21.3 或 1q23.3 扩增的细胞中的 MCL1 或含有死亡效应结构域的蛋白 (DEDD),可抑制细胞增殖。我们还发现,MCL1 或 DEDD 的过表达增加了非扩增尿路上皮癌细胞系 RT112 的锚定非依赖性生长和实验性转移。MCL1 的表达赋予了对多种凋亡诱导剂的抗性,而 DEDD 的表达导致了对 TNFα 诱导的凋亡的抗性。这些观察结果确定了和作为导致侵袭性尿路上皮癌的基因。意义:这些研究确定了和作为导致侵袭性尿路上皮癌的基因。